BioCryst Pharma (NASDAQ:BCRX) Stock

BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals Inc

On Monday, BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) released results from an interim analysis of the ongoing APeX-P trial.
The study centered on an oral granule formulation of once-daily Orladeyo (berotralstat) in pediatric patients. The patients have hereditary angioedema (HAE) <a href="https://www.benzinga.com/pressreleases/25/02/g43907577/biocryst-announces-positive-results-from-apex-p-trial-for-orladeyo-berotralstat-in-pediatric-patie" target="_blank" rel="noreferrer noopener">aged 2 to 12 years</a>.
<ul>
<li>ORLADEYO was safe and well tolerated in APeX-P, with no new safety signals identified. Adverse events (AEs) were similar across all ages and weights.</li>
<li>ORLADEYO resulted in early and sustained reductions in monthly attack rates. After one month of taking ORLADEYO, the median and mean monthly attack rates dropped to 0 and 0.5, respectively. The median monthly attack rate remained at 0 through month 12, and the mean monthly attack rate at month 12 was 0.3.</li>
</ul>
The company also announced new real-world evidence with Orladeyo showing statistically significant HAE attack rate reductions experienced by patients with HAE with C1-INH deficiency (HAE Type I/II) and normal C1-INH levels and function (HAE-nl-C1-INH).
The company plans to submit an FDA marketing application this year.
Concurrently, BioCryst reported fourth-quarter sales of $131.53 million, up 41% year over year, beating the consensus of $130.15 million.
The company reported an adjusted loss of 13 cents per share, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 6 cents per share</a>.
Orladeyo net revenue increased 36.6% to $124.2 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43908737/biocryst-reports-fourth-quarter-and-full-year-2024-financial-results-and-upcoming-key-milestones" rel="noreferrer noopener">and 34% to $437.7 million</a>.
BioCryst expects 2025 sales of $560 million—$575 million, compared to the prior guidance of $540 million—$560 million and the consensus of $545.31 million.
The company increased its 2025 outlook for Orladeyo revenue to between $535 million and $550 million, from $515 million to $535 million.
The company expects to approach quarterly positive EPS and cash flow in the second half of 2025 and to be profitable on an EPS basis, with positive cash flow, for the full year 2026.
Price Action: BCRX stock is down 11.4% at $8.16 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43911341/owens-corning-reports-robust-q4-performance-forecasts-mid-20-revenue-growth-for-q1-2025" target="_blank" rel="noreferrer noopener">Owens Corning Q4 Earnings: Sales Jump 23%, EPS Beats Estimates, Forecasts Mid 20% Revenue Growth For Q1</a></li>
</ul>
Image: Shutterstock

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

BCRX

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

WIIM

BioCryst Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Financial Outlook for 2025
Based on the early signs we are seeing that many more of our Medicare patients are able to afford paid therapy in 2025, and the strong patient demand for ORLADEYO to start the year, the company has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million (previously $515 million to $535 million). The company now expects full year 2025 total revenue (including RAPIVAB (peramivir injection)) will be between $560 million and $575 million (previously $540 million to $560 million).
The increased guidance for ORLADEYO revenues in 2025 also results in an increase in related operating expenses, primarily related to cost of goods sold, distribution costs and higher incentive compensation. The company reiterates the previously provided 2025 non-GAAP operating expense outlook range of $425 million to $435 million (not including stock-based compensation). The revenue related operating expense increases are captured at the higher end of this range.

BioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515M-$535M

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.06) by 116.67 percent. This is a 53.57 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $131.53 million which beat the analyst consensus estimate of $130.15 million by 1.07 percent. This is a 40.83 percent increase over sales of $93.40 million the same period last year.

BioCryst Pharma Q4 2024 Adj EPS $(0.13) Misses $(0.06) Estimate, Sales $131.53M Beat $130.15M Estimate

HAE Attack Rates in Pediatric Patients 2 to &lt;12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P
<ul>
<li>ORLADEYO was safe and well tolerated in APeX-P, with no new safety signals identified. Adverse events (AEs) were similar across all ages and weights.</li>
<li>ORLADEYO resulted in early and sustained reductions in monthly attack rates. The median (range) and mean (±SEM) monthly attack rates in the standard-of-care period were 0.96 (0–5.0) and 1.5 (±0.2) attacks/month, respectively. After one month of taking ORLADEYO, median and mean monthly attack rates dropped to 0 (0-4.0) and 0.5 (±0.2), and the median monthly attack rate remained at 0 through month 12 (month 12 range: 0-1.7); the mean monthly attack rate at month 12 was 0.3 (±0.1).</li>
<li>Eighty-three percent of participants experienced symptom onset before six years of age and 90 percent were diagnosed with HAE in the same timeframe.</li>
</ul>

BioCryst Pharmaceuticals Announced Results From An Interim Analysis Of The Ongoing Apex-p Clinical Trial Evaluating An Oral Granule Formulation Of Once-daily Orladeyo (Berotralstat) In Pediatric Patients With Hereditary Angioedema Aged 2 To <12 Years

<h3>Companies Reporting Before The Bell</h3>
• Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $416.02 million. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $110.85 million. 
• Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) is projected to report earnings for its fourth quarter. 
• Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $645.84 million. 
• BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $127.72 million. 
• Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is expected to report quarterly earnings at $4.95 per share on revenue of $1.48 billion. 
• Gran Tierra Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GTE#AMEX">GTE</a>) is projected to report earnings for its fourth quarter. 
• Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $1.08 billion. 
• Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) is estimated to report quarterly earnings at $1.18 per share on revenue of $2.96 billion. 
• Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) is likely to report quarterly earnings at $2.90 per share on revenue of $2.77 billion. 
• Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $1.03 billion. 
• Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report quarterly earnings at $3.35 per share on revenue of $1.52 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $6.46 million. 
• Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $1.01 billion. 
<h3>Companies Reporting After The Bell</h3>
• DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) is likely to report quarterly loss at $0.29 per share on revenue of $140.50 million. 
• Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $559.19 million. 
• Clean Energy Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $99.87 million. 
• Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $78.20 million. 
• Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $159.89 million. 
• Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $281.61 million. 
• Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $469.68 million. 
• Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) is likely to report quarterly loss at $0.75 per share on revenue of $331.06 million. 
• Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $1.39 billion. 
• Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $91.03 million. 
• Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) is likely to report quarterly loss at $0.27 per share on revenue of $130.25 million. 
• BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) is likely to report quarterly earnings at $0.81 per share on revenue of $720.47 million. 
• SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $684.39 million. 
• ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $6.77 billion. 
• Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.03 million. 
• Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $101.15 million. 
• EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $133.83 million. 
• Cannae Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNNE#NYSE">CNNE</a>) is projected to report quarterly loss at $0.29 per share on revenue of $105.90 million. 
• Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $116.68 million. 
• Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $1.59 billion. 
• Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $1.35 billion. 
• Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $1.69 billion. 
• HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $73.55 million. 
• Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $213.34 million. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $326.77 million. 
• Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) is likely to report quarterly loss at $0.19 per share on revenue of $885.10 million. 
• Haverty Furniture Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $182.09 million. 
• JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $488.74 million. 
• ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $274.56 million. 
• Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is estimated to report quarterly loss at $1.09 per share on revenue of $58.34 million. 
• Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $441.87 million. 
• Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $53.10 million. 
• Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) is projected to report quarterly loss at $0.06 per share on revenue of $19.03 million. 
• Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) is projected to report quarterly loss at $0.15 per share on revenue of $200.55 million. 
• Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) is expected to report quarterly earnings at $1.35 per share on revenue of $278.36 million. 
• Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $175.99 million. 
• Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) is likely to report quarterly earnings at $2.63 per share on revenue of $424.40 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report earnings for its fourth quarter. 
• Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $114.99 million. 
• LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $42.81 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $1.19 billion. 
• Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $155.23 million. 
• MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $289.38 million. 
• SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) is projected to report quarterly loss at $0.14 per share on revenue of $46.89 million. 
• Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $83.69 million. 
• Tortoise Capital Series Trust Tortoise Power and Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPZ#NYSE">TPZ</a>) is expected to report earnings for its fourth quarter. 
• Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) is likely to report quarterly loss at $0.48 per share on revenue of $174.58 million. 
• Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $311.66 million. 
• Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) is projected to report quarterly earnings at $4.22 per share on revenue of $1.18 billion. 
• Clearway Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>) is expected to report earnings for its fourth quarter. 
• V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.10 billion. 
• Veris Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRE#NYSE">VRE</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $66.81 million. 
• GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.98 billion. 
• Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) is projected to report quarterly earnings at $0.19 per share on revenue of $171.47 million. 
• Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) is estimated to report quarterly earnings at $1.88 per share on revenue of $1.29 billion. 
• Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) is expected to report quarterly loss at $0.44 per share on revenue of $4.54 billion. 
• Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $43.47 million. 
• KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $2.00 billion. 
• Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $220.06 million. 
• Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is likely to report quarterly earnings at $3.58 per share on revenue of $3.51 billion. 
• Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $324.82 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

AESI

AORT

APLE

AROC

AZUL

BOOM

BRDG

BWXT

BYON

CHGG

CIVI

CLNE

CNNE

CRGO

CTRA

CWEN

EVER

FANG

FARO

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HLIO

HSTM

ISPO

JBTM

KSPI

LINC

MODG

MYGN

NTST

NVTS

OPAD

PLOW

PRIM

RIOT

SBAC

SIBN

SMMT

TCOM

TREX

UCTT

VCYT

VNOM

WLKP

Earnings Scheduled For February 24, 2025

Biocryst PharmaceuticalsS ays Infarmed In Portugal Has Recommended ORLADEYO (Berotralstat) For The Routine Prevention Of Recurrent Attacks Of Hereditary Angioedema In Eligible Patients 12 Years And Older

Biocryst Pharmaceuticals Announces The Company Will Present Five Abstracts Featuring New Clinical And Real-World Outcomes With Oral, Once-Daily Orladeyo For The Prophylactic Treatment Of Hereditary Angioedema At The 2025 American Academy Of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress.

JMP Securities analyst Jonathan Wolleben reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Market Outperform and maintains $18 price target.

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target

Evercore ISI Group analyst Liisa Bayko maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and raises the price target from $10 to $12.

Evercore ISI Group Maintains Outperform on BioCryst Pharma, Raises Price Target to $12

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and raises the price target from $14 to $15.

Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $15

BioCryst Says ORLADEYO Net Revenue Expected Between $515M-$535M In 2025, Total revenue (Including RAPIVAB) Will Be $540M-$560M

BioCryst Pharmaceuticals, Inc.&nbsp;(Nasdaq:&nbsp;BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO&#xAE;&nbsp;(berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
"The positive HSE recommendation of ORLADEYO&nbsp;broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Ireland," said Charlie Gayer, chief commercial officer of BioCryst.
The HSE decision in Ireland follows the European Commission marketing authorization of ORLADEYO in April 2021. To date, ORLADEYO is licensed in 44 countries.

Government

Regulations

BioCryst's ORLADEYO Gets Ireland's Approval: Expanding Access to Once-Daily HAE Therapy

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and maintains $10 price target.

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $14 price target.

Needham Reiterates Buy on BioCryst Pharma, Maintains $14 Price Target

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $7 to $8.

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

CVKD

DERM

IART

IRON

NGNE

NUWE

OMIC

THRD

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

BioCryst Pharma shares are trading lower following mixed Q3 financial results.

Financial Outlook for 2024
Based on the strength of patient demand for ORLADEYO seen in the third quarter, and expected continued strength in the fourth quarter, the company is adjusting its outlook for full year 2024 global net ORLADEYO revenue to be between $430 million and $435 million (top end of prior range) and introducing full-year 2024 total revenue guidance of between $443 and $448 million based on additional 2024 RAPIVAB revenue.

BioCryst Adjusts ORLADEYO Revenue Guidance To $430M-$435M, Sees Total Product Revenue Of $443M-$448M

Press Releases

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Economics

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present at Upcoming Investor Conferences

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Comments

BioCryst Pharma

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL